These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23289682)

  • 1. Building an ethical foundation for first-in-human nanotrials.
    Dresser R
    J Law Med Ethics; 2012; 40(4):802-8. PubMed ID: 23289682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine first-in-human research: challenges for informed consent.
    King NM
    J Law Med Ethics; 2012; 40(4):823-30. PubMed ID: 23289684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concepts of risk in nanomedicine research.
    Hogle LF
    J Law Med Ethics; 2012; 40(4):809-22. PubMed ID: 23289683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond human subjects: risk, ethics, and clinical development of nanomedicines.
    Kimmelman J
    J Law Med Ethics; 2012; 40(4):841-7. PubMed ID: 23289686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment.
    Wolf SM
    J Law Med Ethics; 2012; 40(4):712-5. PubMed ID: 23289676
    [No Abstract]   [Full Text] [Related]  

  • 6. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.
    Fung RK; Kerridge IH
    Bioethics; 2013 Feb; 27(2):89-96. PubMed ID: 21726264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A portrait of nanomedicine and its bioethical implications.
    Hall RM; Sun T; Ferrari M
    J Law Med Ethics; 2012; 40(4):763-79. PubMed ID: 23289679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical issues in nanomedicine: Tempest in a teapot?
    Allon I; Ben-Yehudah A; Dekel R; Solbakk JH; Weltring KM; Siegal G
    Med Health Care Philos; 2017 Mar; 20(1):3-11. PubMed ID: 27522374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prudent precaution in clinical trials of nanomedicines.
    Marchant GE; Lindor RA
    J Law Med Ethics; 2012; 40(4):831-40. PubMed ID: 23289685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field.
    Fatehi L; Wolf SM; McCullough J; Hall R; Lawrenz F; Kahn JP; Jones C; Campbell SA; Dresser RS; Erdman AG; Haynes CL; Hoerr RA; Hogle LF; Keane MA; Khushf G; King NM; Kokkoli E; Marchant G; Maynard AD; Philbert M; Ramachandran G; Siegel RA; Wickline S
    J Law Med Ethics; 2012; 40(4):716-50. PubMed ID: 23289677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An empirical examination of the current state of publically available nanotechnology guidance materials.
    Fleege L; Lawrenz F
    J Law Med Ethics; 2012; 40(4):751-62. PubMed ID: 23289678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing safety in clinical and translational research.
    Sugarman J
    IRB; 2013; 35(1):15-7. PubMed ID: 23424822
    [No Abstract]   [Full Text] [Related]  

  • 13. Responsible conduct in nanomedicine research: environmental concerns beyond the common rule.
    Resnik DB
    J Law Med Ethics; 2012; 40(4):848-55. PubMed ID: 23289687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Questions concerning the clinical translation of cell-based interventions under an innovation pathway.
    Sugarman J
    J Law Med Ethics; 2012; 40(4):945-50. PubMed ID: 23289697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 360 Degrees of human subjects protections in community-engaged research.
    Ross LF
    Sci Transl Med; 2010 Aug; 2(45):45cm23. PubMed ID: 20720214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of proposed changes in the "Common Rule" for -clinical and translational researchers.
    Selker HP; Pienta KJ
    Clin Transl Sci; 2011 Oct; 4(5):312-3. PubMed ID: 22029799
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical issues in clinical trials involving nanomedicine.
    Resnik DB; Tinkle SS
    Contemp Clin Trials; 2007 Jul; 28(4):433-41. PubMed ID: 17166777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upstream ethics in nanomedicine: a call for research.
    Khushf G
    Nanomedicine (Lond); 2007 Aug; 2(4):511-21. PubMed ID: 17716134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethics in nanomedicine.
    Resnik DB; Tinkle SS
    Nanomedicine (Lond); 2007 Jun; 2(3):345-50. PubMed ID: 17716179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the level of risk in pediatric research: an ethical examination of the federal regulations.
    Dyson M; Parsi K
    J Clin Ethics; 2010; 21(3):212-20. PubMed ID: 21089990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.